PepFellas Laboratories | Research-Grade Peptides
PEPFELLAS Laboratories • Est. 2026
Research Wiki / Peptide Profile
Peptide Profile

Semaglutide

Semaglutide is a synthetic, long-acting 31-amino-acid analogue of human Glucagon-Like Peptide-1 (GLP-1). It is a selective GLP-1 receptor agonist widely used in medicine and metabolic research for glycemic control, chronic weight management, and cardiovascular risk reduction.

1. Chemical Structure and Biochemistry

Native human GLP-1 has an extremely short plasma half-life of roughly 2 minutes due to rapid cleavage by DPP-4 enzymes. Semaglutide overcomes this through three targeted modifications:

  • DPP-4 Resistance: Substitution of alanine at position 8 with $\alpha$-aminoisobutyric acid (Aib) prevents enzymatic cleavage.
  • Stabilization: Substitution of lysine at position 34 with arginine ensures site-specific acylation.
  • Albumin Binding: Conjugation of a C18 fatty diacid chain to lysine at position 26 via a hydrophilic spacer allows strong reversible binding to serum albumin, extending the elimination half-life to approximately 7 days.

2. Mechanism of Action

Semaglutide selectively binds to and activates the GLP-1 receptor (GLP-1R) across pancreatic, gastrointestinal, and central nervous system tissues.

  • Glucose-Dependent Insulin Secretion: Stimulates pancreatic $\beta$-cells to secrete insulin strictly when blood glucose is elevated, while simultaneously suppressing inappropriate glucagon release from $\alpha$-cells.
  • Appetite & Gastric Motility: Slows gastric emptying to blunt postprandial glucose excursions and activates GLP-1 receptors in the hypothalamus and hindbrain to reduce appetite, cravings, and overall energy intake.

3. Research and Applications

Semaglutide is one of the most extensively studied incretin therapies in modern endocrinology.

  • Type 2 Diabetes & Obesity: FDA-approved under brand names including Ozempic (injectable T2D), Rybelsus (oral T2D formulated with SNAC absorption enhancer), and Wegovy (chronic weight management).
  • Cardiorenal & Hepatic Research: Demonstrated significant reductions in major adverse cardiovascular events (MACE) and is actively investigated for metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, and neuroinflammation.
Tags: Semaglutide GLP-1-receptor-agonist GLP-1R incretin-mimetic Ozempic Wegovy Rybelsus type-2-diabetes weight-management acylated-peptide